PDF) A Controlled Trial of Erenumab for Episodic Migraine
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study - Shuu-Jiun Wang, Artemio A Roxas, Bibiana Saravia,
Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine | Novartis
A Controlled Trial of Erenumab for Episodic Migraine | NEJM
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine - David W Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lanteri-Minet, Vera Osipova, Kerry Palmer, Hernan Picard, Daniel D
JCM | Free Full-Text | Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
A Controlled Trial of Erenumab for Episodic Migraine | NEJM
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study | Journal of Neurology, Neurosurgery & Psychiatry
Frontiers | Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies | Novartis
Migraine prevention with erenumab | TCRM
Long-term Efficacy and Safety of Erenumab | Neurology
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study - The Lancet
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial - The Lancet
Methodologies and outcomes of clinical trials of erenumab in episodic... | Download Scientific Diagram
Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study - touchNEUROLOGY
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle - Dodick - Headache: The Journal of Head and Face Pain - Wiley
Erenumab: First-in-Class Approved for Migraine Prevention
Aimovig® (erenumab-aooe) for the Preventive Treatment of Migraine in Adults
Early onset of efficacy with erenumab in patients with episodic and chronic migraine | The Journal of Headache and Pain | Full Text
Study design of the episodic migraine trial (a) and the chronic... | Download Scientific Diagram
![PDF] Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2b5d2470ef97a1399bd34d281f9f37ddf42e79f0/4-Figure1-1.png "PDF] Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study | Semantic Scholar")
PDF] Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study | Semantic Scholar
Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice | SpringerLink
One-year sustained efficacy of erenumab in episodic migraine | Neurology
